Global Coronary Stents Industry

  • October 2011
  • -
  • Global Industry Analysts

This report analyzes the worldwide markets for Coronary Stents in US$ Million and Thousand Units by the following Product Segments: Bare Metal Stents, and Drug Eluting Stents. The report provides separate comprehensive analytics for the US, Japan, Europe, Asia Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets.The report profiles 53 companies including many key and niche players such as Angiotech Pharmaceuticals, Abbott Vascular, Biosensors International, Boston Scientific Corp., Cordis Corporation, Medtronic, Inc., Medtronic Cardiovascular, Inc., OrbusNeich, and Terumo Europe N.V. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table Of Contents





1. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation and Reporting Level 3
Quantitative Techniques and Analytics 3
Product Definitions and Scope of Study 3
Bare Metal Stents 3
Drug Eluting Stents 4

2. GLOBAL MARKET OVERVIEW 5
Growth Revives as Drug Eluting Stents Bounce Back 5
What’s Next on Cards in Coronary Stent Market? 5
Market Snapshots 6
Current and Future Analysis 7
Drug Eluting Stents Steal the Show 7
Star Player JandJ to Quit DES Business in an Expensive Market
Withdrawal 8

3. MARKET TRENDS AND ISSUES 9
Drug Eluting Stent System - Safety Concerns 9
Declining Prices - A Major Concern 9
Restenosis - the Real Growth Driver 9
Small Vessels - A Major Cause of Restenosis 10
Aging Population Propels Coronary Stent Market 10
Next Generation Stents - A Boon for Treating Coronary Diseases 10
Direct Stenting Systems Spur Growth 11
Drug Choice Impacts Market Entry 11
Threats to Coronary Stents - Alternative Therapies/Devices 11
Cell Transplantation - A Major Threat to Coronary Stents 11
Coronary Stents Market Challenged by Drug Therapy 12

4. COMPETITIVE ANALYSIS 13
Coronary Stents - Leading Players 13
Table 1: Leading Players in the Global Coronary Stents Market
(2010 and 2012) - Percentage Breakdown of Market Share by
Company - Boston Scientific, Abbott (Guidant), Johnson and
Johnson, Medtronic, and Others (includes corresponding
Graph/Chart) 13
Bare Metal Stents - Leading Players 14
Table 2: Leading Players in the Global Bare Metal Stents
Market (2010) - Percentage Breakdown of Share for Abbott,
Johnson and Johnson, Boston Scientific, Medtronic, and Others
(includes corresponding Graph/Chart) 14
Drug-Eluting Stents - Leading Players 14
Table 3: Global Drug Eluting Stents Market (2010): Percentage
Breakdown of Share by Company - Boston Scientific, Abbott
Labs, Johnson and Johnson, Medtronic, Others (includes
corresponding Graph/Chart) 14
Major DES Types in the Market and Leading Manufacturers 14
Comparative Analysis of the Leading Players 15

5. CORONARY DISEASE - A PERSPECTIVE 16
Factors Responsible for Coronary Diseases 16
Controllable Risk Factors 16
High Blood Cholesterol 16
Sedentary Life Style and Habits 16
Smoking Habits 17
High Blood Pressure 17
Uncontrollable Risk Factors 17
Age 17
Heredity 17
Gender 17
Causative Risk Factors 17
Stress and Anger 18
Obesity 18
Diabetes 18
Symptoms of Coronary Artery Disease 18
Diagnosis 18
Treatment 19
Drug Supported Treatments 19
Invasive Treatments 19
Bypass Surgery 19
Percutaneous Transluminal Coronary Angioplasty (Balloon
Angioplasty) 19
Natural Therapy 20
Coronary Angioplasty Suitable for Acute Myocardial Infarction 20
Advancements in Coronary Disease Treatment Modalities 20
University of Virginia’s Microbe Solution for Post Surgical
Complications 20
Radiation for Re-clogged Arteries Show Promise 21
Radioactive Coronary Stents Promise Bright Future 21

6. CORONARY STENTS - PRODUCT OVERVIEW 22
Introduction 22
Evolution of Coronary Stents 22
Applications of Coronary Stents 22
Stent Deployment 23
Key Stent Delivery Platforms by Select Company 24
Coronary Stent Designs 24
Key Factors Determining Coronary Stent Performance 24
Delivery Convenience 24
Efficient Scaffolding 24
Radiopacity (Visibility) 25
Optimum Flexibility 25
Shape Conformability 25
Material for Coronary Stent 25
Risk Associated with Stenting 25
Improper Stent Implantation Likely Cause for In-Stent Restenosis 26
Precautions 27
Direct Coronary Stenting - Creating an Enliven 27
Limitations 27
Regulatory Approvals Wooing Stent Market 28
A Peek into Regulatory Approvals for Coronary Stents 28

7. PRODUCT SEGMENTS 30
Bare Metal Stents 30
Major Bare Metal Stents by Company 30
Drug-Eluting Stents 30
DE Stents Overshadow Intravascular Brachytherapy Interventions 31
Major Drug-Eluting Stents by Company 31
Drugs for Coating DESs 31
Cytotoxic or Cytostatic Drug - the Debate Continues 32
Dosing and Deliverability Crucial for DES 32
Polymer Coatings for Effective Dosing and Deliverability 32
Drugs Used for DES by Major Competitors in the Stent Market 32
Leading Coronary Stent Brands 33
Cypher 33
Structure and Delivery Mechanism 33
Taxus 34
Structure and Delivery Mechanism 34

8. RESEARCH AND DEVELOPMENT 35
Extensive RandD Underway in Global Drug-Eluting Stents Market 35
At the Labs 35
Other Products Under Trials - A Recent Past Perspective 35
OMT Developing R-stent 35
Reva Developing Stainless Steel Bare-Metal Stent 35
DandP Corp Developing Bovine Pericardium- Covered Stent 36
Advanced Bio Synthesizing Porous Drug-Eluting Stents 36
Lombard Medical Developing PEP Coatings 36
Shiga Develops Biodegradable Drug-Eluting Stent 36

9. PRODUCT INNOVATIONS/INTRODUCTIONS 37
Boston Scientific Launches IONâ„¢ Platinum Chromium Stent System 37
Terumo Introduces Nobori Drug-Eluting Coronary Stent 37
Boston Scientific Unveils TAXUS® Element™ and PROMUS® Element™
Stent Systems 37
Covidien Introduces EverFlex+â„¢ Self-Expanding Peripheral Stent
System 38
Boston Scientific Launches Taxus Element Stent System in
European Union 38
Cordis Introduces PRESILLIONâ„¢ PLUS Stent System in Europe 38
Medtronic Launches Resolute Integrity Stent System 38
InspireMD Unveils MGuard Prime 39
Boston Scientific Introduces Taxus Eluting Stent System 39
Boston Scientific Unveils TAXUS Liberte Paclitaxel Eluting
Stent System in Japan 39
Alvimedica Launches Coracto Drug-Eluting Stent in Europe 39
Abbott Labs to Launch XIENCE V in China 40
Medtronic Launches Driver Sprint RX Coronary STENT System 40
Existent Introduces Premier Coronary Stent System 40
Medtronic to Unveil Balloon Catheter Systems and Coronary Stents 40
NanoInterventions Launches Mouse Stent Model 40
InspireMD - MGuardâ„¢ Coronary Stent Launched in Italy 41
CeloNova BioSciences Launches CATANIAâ„¢ Coronary Stent with
NanoThin Polyzene®-F 41
Angiotech Launches Cook Medical’s Drug Eluting Zilver® PTX™
Stent in New Zealand 41

10. RECENT INDUSTRY ACTIVITY 42
Boston Scientific Receives FDA Approval for Novel Paclitaxel-
Eluting Coronary Stent 42
Boston Scientific Receives Approval for Distribution of
PROMUS® Everolimus-Eluting Stent 42
Cordis Discontinues Production of NEVOâ„¢ Sirolimus- Eluting
Coronary Stents 42
Boston Scientific Receives FDA Approval for ION Stent 43
Abbott Obtains FDA Approval to Extend RX ACCULINK® Carotid
Stent System Application 43
Boston Scientific Receives CE Mark Approval for OMEGAâ„¢
Platinum Chromium Stent System 43
Stentys Launches Stents across Additional Countries in Europe 44
Opto Circuits Acquires N.S. Remedies 44
Biosensors International Group Takes Over Assets of Devax 44
Cordis Signs Distribution Agreement with Ostial Solutions 44
Medtronic Obtains FDA Approval for Integrity Coronary Stent
System 44
Boston Scientific Receives Approval from Japanese MHLW for
PROMUS® Coronary Stent 45
InspireMD Selects Kirloskar Technologies for Distributing
Coronary Stent Systems 45
Boston Scientific Expands PROMUS® Everolimus-Eluting Coronary
Stent System 45
Boston Scientific Receives TGS Approval from Australia 46
Svelte Medical Systems Commences Clinical Trial of SOAW
Delivery System 46
Abbott Receives Japan's MHLW Approval for Xience V 46
Opto Circuits Receives Mark Approval from Communite European 46
Abbott Receives Health Canada Approval for XIENCE V® Stent System 46
Medtronic Secures Japan's MHLW Approval for Endeavor® Drug
Eluting Stent 47
Boston Scientific Takes Over Labcoat 47
Micell and Maxcor Sign Strategic Agreement 47
Cordis Receives FDA Approval for Variant of Cypher Sirolimus-
Eluting Coronary Stent 47
Boston Scientific Obtains CE Mark Approval for Promus Element
Everolimus-Eluting Coronary Stent System 47
Cypher Select® Plus Sirolimus-eluting Coronary Stent Gains CE
Mark for Treatment in Diabetic Patients 48
Atrium Medical Obtains CE Mark for Cinatraâ„¢ 48
Medtronic Secures CE Mark Approval for Endeavor Drug-Eluting
Stent for Use in Treatment of ACS 48
CorNova® Obtains CE mark approval for Valecor Platinum
Coronary Stent System 48
Cook Medical Receives CE Mark Approval and Launches Zilver®
PTX® Drug-Eluting Peripheral Stent 49
Disa Receives CE Approval for Coronary Stent 49
Datascope Acquires Peripheral Stent Business of Sorin Group 49
Boston Scientific Receives FDA approval for TAXUS® Liberte®
Drug-Eluting STENT 49
Abbott Labs Receives FDA Approval for Xience V 49
Bard to Purchase Assets of LifeStent Product Portfolio 50
Medtronic Receives the US FDA Approval to Use Endeavor® Stent 50
Medtronic Inc. Receives Approval for its Drug-Eluting Stent,
“Endeavor” In Canada 50
Boston Scientific to Market TAXUS® Liberte® Stent System in
Canada 50
Abbott Applies for Approval of XIENCEâ„¢ V in Japan 51
Medinol Achieves CE Mark Approval for Presillionâ„¢ Cobalt
Chromium Coronary Stent System 51
Iberhospitex Receives Spanish Approval to Sell Palau Pharma’s
“Active” Coronary Stent 51
Clearstream’s Intrepide Drug Eluting Stent of Clearstream
Receives CE mark approval 51
Terumo Introduces Its Drug-Eluting Stent in Germany and Marks
Its European Entry 52
Tryton Medical’s Side-Branch Stent Achieves CE Mark Approval 52
CV Therapeutics Offers its Stent Coating Technology to
Medlogics Device Corporation 52
Abbott’s 2.25mm-Sized XIENCE™ V Drug Eluting Stent receives CE
Mark of Approval 52
Biosensors Receives CE Mark Approval for BioMatrix® Stent System 53
Nfocus Neuromedical’s CardioVasc™ Stent-Graft and Delivery
System Receives CE Mark Approval 53

11. FOCUS ON SELECT GLOBAL PLAYERS 54
Angiotech Pharmaceuticals (Canada) 54
Abbott Vascular (USA) 54
Biosensors International (USA) 54
Boston Scientific Corp. (USA) 55
Cordis Corporation (JNJ) - (USA) 55
Medtronic, Inc. (USA) 56
Medtronic Cardiovascular, Inc. (USA) 56
OrbusNeich (Hong Kong) 56
Terumo Europe N.V. (Belgium) 56

12. GLOBAL MARKET PERSPECTIVE 57
Table 4: World Recent Past, Current and Future Analysis for
Coronary Stents By Geographic Region - US, Japan, Europe,
Asia-Pacific (Excluding Japan) and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2009 through 2017 (includes corresponding Graph/Chart) 57

Table 5: World Recent Past, Current and Future Analysis for
Coronary Stents by Geographic Region - US, Japan, Europe,
Asia-Pacific (Excluding Japan) and Rest of World Markets
Independently Analyzed with Annual Sales in Thousand Units for
years 2009 through 2017 (includes corresponding Graph/Chart) 58

Table 6: World Historic Review for Coronary Stents by
Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding
Japan) and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2003 through 2008
(includes corresponding Graph/Chart) 59

Table 7: World Historic Review for Coronary Stents by
Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding
Japan) and Rest of World Markets Independently Analyzed with
Annual Sales in Thousand Units for Years 2003 through 2008
(includes corresponding Graph/Chart) 60

Table 8: World 15-Year Perspective for Coronary Stents by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of
World Markets for Years 2003, 2010 and 2017 (includes
corresponding Graph/Chart) 61

Table 9: World 15-Year Perspective for Coronary Stents by
Geographic Region - Percentage Breakdown of Unit Sales for US,
Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of
World Markets for Years 2003, 2010 and 2017 (includes
corresponding Graph/Chart) 62

Table 10: World Recent Past, Current and Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stents and
Drug Eluting Stents Markets Independently Analyzed with Annual
Sales in US$ Million for years 2009 through 2017 (includes
corresponding Graph/Chart) 63

Table 11: World Recent Past, Current and Future Analysis for
Coronary Stents by Product Segment-Bare Metal Stents and Drug
Eluting Stents Markets Independently Analyzed with Annual
Sales in Thousand Units for years 2009 through 2017 (includes
corresponding Graph/Chart) 64

Table 12: World Historic Review for Coronary Stents by Product
Segment-Bare Metal Stents and Drug Eluting Stents Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2003 through 2008 (includes corresponding Graph/Chart) 65

Table 13: World Historic Review for Coronary Stents by Product
Segment-Bare Metal Stents and Drug Eluting Stents Markets
Independently Analyzed with Annual Sales in Thousand Units for
Years 2003 through 2008 (includes corresponding Graph/Chart) 66

Table 14: World 15-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Dollar Sales for
Bare Metal Stents and Drug Eluting Stents Markets for Years
2003, 2010 and 2017 (includes corresponding Graph/Chart) 67

Table 15: World 15-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Unit Sales for Bare
Metal Stents and Drug Eluting Stents Markets for Years 2003,
2010 and 2017 (includes corresponding Graph/Chart) 68

Table 16: World Recent Past, Current and Future Analysis for
Bare Metal Stents by Geographic Region - US, Japan, Europe,
Asia - Pacific (Excluding Japan) and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2009 through 2017 (includes corresponding Graph/Chart) 69

Table 17: World Recent Past, Current and Future Analysis for
Bare Metal Stents by Geographic Region - US, Japan, Europe,
Asia - Pacific (Excluding Japan) and Rest of World Markets
Independently Analyzed with Annual Sales in Thousand Units for
years 2009 through 2017 (includes corresponding Graph/Chart) 70

Table 18: World Historic Review for Bare Metal Stents By
Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding
Japan) and Rest of World Markets Independently Analyzed with
Annual Sale sin US$ Million for Years 2003 through
2008(includes corresponding Graph/Chart) 71

Table 19: World Historic Review for Bare Metal Stents By
Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding
Japan) and Rest of World Markets Independently Analyzed with
Annual Sales in Thousand Units for Years 2003 through 2008
(includes corresponding Graph/Chart) 72

Table 20: World 15-Year Perspective for Bare Metal Stents by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of
World Markets for Years 2003, 2010 and 2017 (includes
corresponding Graph/Chart) 73

Table 21: World 15-Year Perspective for Bare Metal Stents by
Geographic Region - Percentage Breakdown of Unit Sales for US,
Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of
World Markets for Years 2003, 2010 and 2017 (includes
corresponding Graph/Chart) 74

Table 22: World Recent Past, Current and Future Analysis for
Drug Eluting Stents by Geographic Region - US, Japan, Europe,
Asia - Pacific (Excluding Japan), and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2009 through 2017 (includes corresponding Graph/Chart) 75

Table 23: World Recent Past, Current and Future Analysis for
Drug Eluting Stents by Geographic Region - US, Japan, Europe,
Asia - Pacific (Excluding Japan), and Rest of World Markets
Independently Analyzed with Annual Sales in Thousand Units for
Years 2009 through 2017 (includes corresponding Graph/Chart) 76

Table 24: World Historic Review for Drug Eluting Stents by
Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding
Japan) and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2003 through 2008
(includes corresponding Graph/Chart) 77

Table 25: World Historic Review for Drug Eluting Stents by
Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding
Japan) and Rest of World Markets Independently Analyzed with
Annual Sales in Thousand Units for Years 2003 through 2008
(includes corresponding Graph/Chart) 78

Table 26: World 15-Year Perspective for Drug Eluting Stents by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of
World Markets for Years 2003, 2010 and 2017 (includes
corresponding Graph/Chart) 79

Table 27: World 15-Year Perspective for Drug Eluting Stents by
Geographic Region - Percentage Breakdown of Unit Sales for US,
Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of
World Markets for Years 2003, 2010 and 2017 (includes
corresponding Graph/Chart) 80

13. THE UNITED STATES 81
A.Market Analysis 81
Largest Market Worldwide 81
Coronary Artery Disease - A US Perspective 81
Baby Boomers Boost Coronary Stent Market 81
Revival in the DES Market 81
Reimbursement System 82
National Average Medicare Payment For DRGS 82
Competitive Scenario 82
Leading Players 82
Coronary Stents - Boston Scientific and JNJ Battle for
Dominance 82
Table 28: Leading Players in the US Coronary Stents
Market (2010) - Percentage Breakdown of Share for Boston
Scientific, Abbott and Johnson and Johnson (includes
corresponding Graph/Chart) 83
Drug Eluting Stents - Competition in the Brewing 83
Table 29: Leading Players in the US Drug-Eluting Stents
Market (2010) - Percentage Breakdown of share for Boston
Scientific, Abbott Labs, JandJ-Cordis and Medtronic
(includes corresponding Graph/Chart) 83
Regulatory Environment 84
B.Market Analytics 84
Table 30: US Recent Past, Current and Future Analysis for
Coronary Stents by Product Segment - Bare Metal and Drug
Eluting Stent Markets Independently Analyzed with Annual
Sales in US$ Million for years 2009 through 2017 (includes
corresponding Graph/Chart) 84

Table 31: US Recent Past, Current and Future Analysis for
Coronary Stents by Product Segment - Bare Metal and Drug
Eluting Stent Markets Independently Analyzed with Annual
Sales in Thousand Units for years 2009 through 2017
(includes corresponding Graph/Chart) 85

Table 32: US Historic Review for Coronary Stents by Product
Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2003 through 2008 (includes corresponding Graph/Chart) 86

Table 33: US Historic Review for Coronary Stents by Product
Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in Thousand Units
for years 2003 through 2008 (includes corresponding
Graph/Chart) 87

Table 34: US 15-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Dollar Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2003, 2010 and 2017 (includes corresponding Graph/Chart) 88

Table 35: US 15-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Unit Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2003, 2010 and 2017 (includes corresponding Graph/Chart) 89

14. JAPAN 90
A.Market Analysis 90
Prospects Weighed down by Regulatory Entanglements 90
Japanese Coronary Stents Command Higher Prices 90
Table 36: Coronary Stent Pricing (2008): Comparative
Analysis of Prices in Japan, US, Europe and Global Average
(includes corresponding Graph/Chart) 90
Competitive Landscape 91
Table 37: Leading Players in the Japanese Coronary Stent
Market ( 2010) - Percentage Breakdown of Share for Johnson and
Johnson, Medtronic, Boston Scientific, and Others
(includes corresponding Graph/Chart) 91

Table 38: Leading Players in the Japanese Bare Metal Stent
Market (2010) - Percentage Breakdown by of Share for
Medtronic, Boston Scientific, JNJ and Others (includes
corresponding Graph/Chart) 92

Table 39: Leading Players in Japanese Drug-Eluting Stent
Market (2010) - Percentage Breakdown of Share for Johnson and
Johnson and Boston Scientific (includes corresponding
Graph/Chart) 92
B.Market Analytics 93
Table 40: Japanese Recent Past, Current and Future Analysis
for Coronary Stents by Product Segment - Bare Metal and Drug
Eluting Stent Markets Independently Analyzed with Annual
Sales in US$ Million for years 2009 through 2017 (includes
corresponding Graph/Chart) 93

Table 41: Japanese Recent Past, Current and Future Analysis
for Coronary Stents by Product Segment - Bare Metal and Drug
Eluting Stent Markets Independently Analyzed with Annual
Sales in Thousand Units for years 2009 through 2017
(includes corresponding Graph/Chart) 94

Table 42: Japanese Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2003 through 2008 (includes corresponding Graph/Chart) 95

Table 43: Japanese Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in Thousand Units
for years 2003 through 2008 (includes corresponding
Graph/Chart) 96

Table 44: Japanese 15-Year Perspective for Coronary Stents
by Product Segment - Percentage Breakdown of Dollar Sales
for Bare Metal Stents and Drug Eluting Stents Markets for
years 2003, 2010 and 2017 (includes corresponding Graph/Chart) 97

Table 45: Japanese 15-Year Perspective for Coronary Stents
by Product Segment - Percentage Breakdown of Unit Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2003, 2010 and 2017 (includes corresponding Graph/Chart) 98

15. EUROPE 99
A.Market Analysis 99
Cardiovascular Disease in Europe - A Perspective 99
Growth Bar Too Low 99
Two-Speed Europe 99
Stent Market’s Merger Mania 100
Dampeners to Rapid Adoption of DES in Europe 100
Competitive Scenario 101
Table 46: Leading Players in the European Drug- Eluting
Stent Market (2010) - Percentage Breakdown of Share for
Johnson and Johnson, Boston Scientific, Medtronic, and Others
(includes corresponding Graph/Chart) 101
B.Market Analytics 102
Table 47: European Recent Past, Current and Future Analysis
for Coronary Stents by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2009 through 2017 (includes corresponding Graph/Chart) 102

Table 48: European Recent Past, Current and Future Analysis
for Coronary Stents by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales in Thousand Units
for years2009 through 2017 (includes corresponding
Graph/Chart) 103

Table 49: European Historic Review for Coronary Stents by
Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets Independently Analyzed
with Annual Sales in US$ Million for years 2003 through 2008
(includes corresponding Graph/Chart) 104

Table 50: European Historic Review for Coronary Stents by
Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets Independently Analyzed
with Annual Sales in Thousand Units for years 2003 through
2008 (includes corresponding Graph/Chart) 105

Table 51: European 15-Year Perspective for Coronary Stents
by Geographic Region - Percentage Breakdown of Dollar Sales
for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2003, 2010 and 2017 (includes
corresponding Graph/Chart) 106

Table 52: European 15-Year Perspective for Coronary Stents
by Geographic Region - Percentage Breakdown of Unit Sales
for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2003, 2010 and 2075 (includes
corresponding Graph/Chart) 107

Table 53: European Recent Past, Current and Future Analysis
for Coronary Stents by Product Segment - Bare Metal and Drug
Eluting Stents Markets Independently Analyzed with Annual
sales in US$ Million for years 2009 through 2017 (includes
corresponding Graph/Chart) 108

Table 54: European Recent Past, Current and Future Analysis
for Coronary Stents by Product Segment - Bare Metal and Drug
Eluting Stents Markets Independently Analyzed with Annual
sales in Thousand Units for years 2009 through 2017
(includes corresponding Graph/Chart) 109

Table 55: European Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2003 through 2008 (includes corresponding Graph/Chart) 110

Table 56: European Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in Thousand Units
for years 2003 through 2008 (includes corresponding
Graph/Chart) 111

Table 57: European 15-Year Perspective for Coronary Stents
by Product Segment - Percentage Breakdown of Dollar Sales
for Bare Metal Stents and Drug Eluting Stents Markets for
years 2003, 2010 and 2017 (includes corresponding Graph/Chart) 112

Table 58: European 15-Year Perspective for Coronary Stents
by Product Segment - Percentage Breakdown of Unit Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2003, 2010 and 2017 (includes corresponding Graph/Chart) 113

15a. FRANCE 114
Market Analysis 114
Table 59: French Recent Past, Current and Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in US$ Million for years 2009 through 2017
(includes corresponding Graph/Chart) 114

Table 60: French Recent Past, Current and Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in Thousand Units for years 2009 through 2017
(includes corresponding Graph/Chart) 115

Table 61: French Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2003 through 2008 (includes corresponding Graph/Chart) 116

Table 62: French Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in Thousand Units
for years 2003 through 2008 (includes corresponding
Graph/Chart) 117

Table 63: French 15-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Dollar Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2003, 2010 and 2017 (includes corresponding Graph/Chart) 118

Table 64: French 15-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Unit Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2003, 2010 and 2017 (includes corresponding Graph/Chart) 119

15b. GERMANY 120
Market Analysis 120
Table 65: German Recent Past, Current and Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in US$ Million for years 2009 through 2017
(includes corresponding Graph/Chart) 120

Table 66: German Recent Past, Current and Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in Thousand Units for years 2009 through 2017
(includes corresponding Graph/Chart) 121

Table 67: German Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2003 through 2008 (includes corresponding Graph/Chart) 122

Table 68: German Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in Thousand Units
for years 2003 through 2008 (includes corresponding
Graph/Chart) 123

Table 69: German 15-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Dollar Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2003, 2010 and 2017 (includes corresponding Graph/Chart) 124

Table 70: German 15-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Unit Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2003, 2010 and 2017 (includes corresponding Graph/Chart) 125

15c. ITALY 126
Market Analysis 126
Table 71: Italian Recent Past, Current and Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) 126

Table 72: Italian Recent Past, Current and Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in Thousand Units for years 2009 through 2017
(includes corresponding Graph/Chart) 127

Table 73: Italian Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2003 through 2008 (includes corresponding Graph/Chart) 128

Table 74: Italian Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in Thousand Units
for years 2003 through 2008 (includes corresponding
Graph/Chart) 129

Table 75: Italian 15-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Dollar Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2003, 2010 and 2017 (includes corresponding Graph/Chart) 130

Table 76: Italian 15-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Unit Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2003, 2010 and 2017 (includes corresponding Graph/Chart) 131

15d. THE UNITED KINGDOM 132
Market Analysis 132
Table 77: UK Recent Past, Current and Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in US$ Million for years 2009 through 2017
(includes corresponding Graph/Chart) 132

Table 78: UK Recent Past, Current and Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in Thousand Units for years 2009 through 2017
(includes corresponding Graph/Chart) 133

Table 79: UK Historic Review for Coronary Stents by Product
Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2003 through 2008 (includes corresponding Graph/Chart) 134

Table 80: UK Historic Review for Coronary Stents by Product
Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in Thousand Units
for years 2003 through 2008 (includes corresponding
Graph/Chart) 135

Table 81: UK 15-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Dollar Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2003, 2010 and 2017 (includes corresponding Graph/Chart) 136

Table 82: UK 15-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Unit Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2003, 2010 and 2017 (includes corresponding Graph/Chart) 137

15e. SPAIN 138
Market Analysis 138
Table 83: Spanish Recent Past, Current and Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in US$ Million for years 2009 through 2017
(includes corresponding Graph/Chart) 138

Table 84: Spanish Recent Past, Current and Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in Thousand Units for years 2009 through 2017
(includes corresponding Graph/Chart) 139

Table 85: Spanish Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2003 through 2008 (includes corresponding Graph/Chart) 140

Table 86: Spanish Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in Thousand Units
for years 2003 through 2008 (includes corresponding
Graph/Chart) 141

Table 87: Spanish 15-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Dollar Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2003, 2010 and 2017 (includes corresponding Graph/Chart) 142

Table 88: Spanish 15-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Unit Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2003, 2010 and 2017 (includes corresponding Graph/Chart) 143

15f. RUSSIA 144
Market Analysis 144
Table 89: Russian Recent Past, Current and Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in US$ Million for years 2009 through 2017
(includes corresponding Graph/Chart) 144

Table 90: Russian Recent Past, Current and Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in Thousand Units for years 2009 through 2017
(includes corresponding Graph/Chart) 145

Table 91: Russian Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2003 through 2008 (includes corresponding Graph/Chart) 146

Table 92: Russian Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in Thousand Units
for years 2003 through 2008 (includes corresponding
Graph/Chart) 147

Table 93: Russian 15-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Dollar Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2003, 2010 and 2017 (includes corresponding Graph/Chart) 148

Table 94: Russian 15-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Unit Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2003, 2010 and 2017 (includes corresponding Graph/Chart) 149

15g. REST OF EUROPE 150
Market Analysis 150
Table 95: Rest of Europe Recent Past, Current and Future
Analysis for Coronary Stents by Product Segment - Bare Metal
Stent and Drug Eluting Stent Markets Independently Analyzed
with Annual Sales in US$ Million for years 2009 through 2017
(includes corresponding Graph/Chart) 150

Table 96: Rest of Europe Recent Past, Current and Future
Analysis for Coronary Stents by Product Segment - Bare Metal
Stent and Drug Eluting Stent Markets Independently Analyzed
with Annual Sales in Thousand Units for years 2009 through
2017 (includes corresponding Graph/Chart) 151

Table 97: Rest of Europe Historic Review for Coronary Stents
by Product Segment - Bare Metal and Drug Eluting Stent
Markets Independently Analyzed with Annual Sales in US$
Million for years 2003 through 2008 (includes corresponding
Graph/Chart) 152

Table 98: Rest of Europe Historic Review for Coronary Stents
by Product Segment - Bare Metal and Drug Eluting Stent
Markets Independently Analyzed with Annual Sales in Thousand
Units for years 2003 through 2008 (includes corresponding
Graph/Chart) 153

Table 99: Rest of Europe 15-Year Perspective for Coronary
Stents by Product Segment - Percentage Breakdown of Dollar
Sales for Bare Metal Stents and Drug Eluting Stents Markets
for years 2003, 2010 and 2017 (includes corresponding
Graph/Chart) 154

Table 100: Rest of Europe 15-Year Perspective for Coronary
Stents by Product Segment - Percentage Breakdown of Unit
Sales for Bare Metal Stents and Drug Eluting Stents Markets
for years 2003, 2010 and 2017 (includes corresponding
Graph/Chart) 155

16. ASIA-PACIFIC 156
A.Market Analysis 156
China - Healthcare Reforms to Propel DES Market 156
Table 101: Coronary Stent Market in China (2010):
Percentage Breakdown of Market Share by Company- Shanghai
Microport, Beijing Lepu, JW Medical, JandJ Cordis, Medtronic
and Others (includes corresponding Graph/Chart) 156
Coronary Stent Market in a Bubble Zone Now 157
Regional Players and their DES Development Efforts 157
Cost Focus Helps Stent Makers Win the Market Stunt 157
B.Market Analytics 158
Table 102: Asia-Pacific Recent Past, Current and Future
Analysis for Coronary Stents by Product Segment - Bare Metal
Stent and Drug Eluting Stent Markets Independently Analyzed
with Annual Sales in US$ Million for years 2009 through 2017
(includes corresponding Graph/Chart) 158

Table 103: Asia-Pacific Recent Past, Current and Future
Analysis for Coronary Stents by Product Segment - Bare Metal
Stent and Drug Eluting Stent Markets Independently Analyzed
with Annual Sales in Thousand Units for years 2009 through
2017 (includes corresponding Graph/Chart) 159

Table 104: Asia-Pacific Historic Review for Coronary Stents
by Product Segment - Bare Metal and Drug Eluting Stent
Markets Independently Analyzed with Annual Sales in US$
Million for years 2003 through 2008(includes corresponding
Graph/Chart) 160

Table 105: Asia-Pacific Historic Review for Coronary Stents
by Product Segment - Bare Metal and Drug Eluting Stent
Markets Independently Analyzed with Annual Sales in Thousand
Units for years 2003 through 2008(includes corresponding
Graph/Chart) 161

Table 106: Asia-Pacific 15-Year Perspective for Coronary
Stents by Product Segment - Percentage Breakdown of Dollar
Sales for Bare Metal Stents and Drug Eluting Stents Markets
for years 2003, 2010 and 2017 (includes corresponding
Graph/Chart) 162

Table 107: Asia-Pacific 15-Year Perspective for Coronary
Stents by Product Segment - Percentage Breakdown of Unit
Sales for Bare Metal Stents and Drug Eluting Stents Markets
for years 2003, 2010 and 2017 (includes corresponding
Graph/Chart) 163

17. REST OF WORLD 164
A.Market Analysis 164
Brazil - Low Penetration of DES 164
South Africa - Leading Players 164
Table 108: Leading Players in South African Coronary Stent
Market (2010) - Percentage Breakdown by Unit Sales for
Johnson and Johnson, Boston Scientific, Guidant, Abbott and
Others (includes corresponding Graph/Chart) 164
B.Market Analytics 165
Table 109: Rest of World Recent Past, Current and Future
Analysis for Coronary Stents by Product Segment - Bare Metal
Stent and Drug Eluting Stent Markets Independently Analyzed
with Annual Sales in US$ Million for years 2009 through 2017
(includes corresponding Graph/Chart) 165

Table 110: Rest of World Recent Past, Current and Future
Analysis for Coronary Stents by Product Segment - Bare Metal
Stent and Drug Eluting Stent Markets Independently Analyzed
with Annual Sales in Thousand Units for years 2009 through
2017 (includes corresponding Graph/Chart) 166

Table 111: Rest of World Historic Review for Coronary Stents
by Product Segment - Bare Metal and Drug Eluting Stent
Markets Independently Analyzed with Annual Sales in US$
Million for years 2003 through 2008 (includes corresponding
Graph/Chart) 167

Table 112: Rest of World Historic Review for Coronary Stents
by Product Segment - Bare Metal and Drug Eluting Stent
Markets Independently Analyzed with Annual Sales in Thousand
Units for years 2003 through 2008 (includes corresponding
Graph/Chart) 168

Table 113: Rest of World 15-Year Perspective for Coronary
Stents by Product Segment - Percentage Breakdown of Dollar
Sales for Bare Metal Stents and Drug Eluting Stents Markets
for years 2003, 2010 and 2017 (includes corresponding
Graph/Chart) 169

Table 114: Rest of World 15-Year Perspective for Coronary
Stents by Product Segment - Percentage Breakdown of Unit
Sales for Bare Metal Stents and Drug Eluting Stents Markets
for years 2003, 2010 and 2017 (includes corresponding
Graph/Chart) 170


COMPETITIVE LANDSCAPE

Total Companies Profiled: 53 (including Divisions/Subsidiaries - 62)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 34
Canada 1
Japan 3
Europe 15
France 1
Germany 5
The United Kingdom 1
Italy 1
Spain 1
Rest of Europe 6
Asia-Pacific (Excluding Japan) 5
Middle-East 2
Africa 2
------------------------------------------

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

MediPoint: Aortic Stent Grafts - Global Analysis and Market Forecasts

MediPoint: Aortic Stent Grafts - Global Analysis and Market Forecasts

  • $ 6 495
  • Industry report
  • October 2014
  • by Global Data

MediPoint: Aortic Stent Grafts - Global Analysis and Market Forecasts Summary Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent ...

Global Aortic Stent Grafts Market 2014-2018

Global Aortic Stent Grafts Market 2014-2018

  • $ 2 500
  • Industry report
  • July 2014
  • by Infiniti Research Limited

About Aortic Stent Grafts An aortic stent graft is a stainless steel metal mesh-like tube composed of woven polyester fabric. Stent grafts are categorized on the basis of product application type into ...

Cardiovascular Device Business SEPTEMBER 2014

Cardiovascular Device Business SEPTEMBER 2014

  • $ 1 114
  • Industry report
  • September 2014
  • by Espicom Business Intelligence

Industry Trend Analysis - ICD/Pacemaker Innovation Will Dampen Biotronik's Long-Term Continuous Monitoring Ambitions Industry Trend Analysis - Cordis' Divestment Only A Matter Of Time Industry Trend Analysis ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.